Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cholesterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 0.89 |
| ▸ | RORC | P51449 | 5/20 | 0.89 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.89 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.89 |
| ▸ | USP2 | O75604 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.89 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.76 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.76 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.75 |
| ▸ | CRYAB | P02511 | 1/20 | 0.73 |
| ▸ | HMGCR | P04035 | 1/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.73 |
| ▸ | ITGAV | P06756 | 1/20 | 0.73 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.73 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.72 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.71 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL3792432 | 1.00 | OSBP (0.89) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL27579873 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL26086800 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL9458834 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL192030 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL1965451 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL29094044 | 0.99 | OSBP (0.91) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL159924 | 0.98 | OSBP (0.89) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL2160402 | 0.98 | OSBP (0.89) | OSBPRORCOSBP2CYP46A1USP2 | |
| Cholesterol SCHEMBL27237461 | 0.98 | OSBP (0.89) | OSBPRORCOSBP2CYP46A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030770-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIV SOUTH FLORIDA (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210030770-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIV SOUTH FLORIDA (US) | 2021-02-04 | — | — | US | disclosed |
| US-10828312-B2 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders | UNIVERSITY OF SOUTH FLORIDA | 2020-11-10 | — | — | US | disclosed |
| US-20200129527-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200129527-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828312-B2 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders | HMGCR, LCAT, MAPT | OSBP 724/4885RORC 254/4885OSBP2 356/4885 |
| US-20210030770-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | HMGCR, LCAT, MAPT | OSBP 724/4885RORC 254/4885OSBP2 356/4885 |
| US-20200129527-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | HMGCR, LCAT, MAPT | OSBP 724/4885RORC 254/4885OSBP2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.